Acrux (ACR) Stock Price, News & Analysis

Company Overview

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4,000 shs
• Average Volume: N/A
• Market Capitalization: $12.47 million
• P/E Ratio: N/A
• Dividend Yield: 11.66%
• Price Target: N/A
• Consensus Rating: N/A

ACR Stock Analysis - Frequently Asked Questions

How were Acrux's earnings last quarter?

Acrux Limited (ASX:ACR) released its quarterly earnings data on Thursday, February, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. Acrux had a negative trailing twelve-month return on equity of 130.13% and a negative net margin of 113.93%.

What other stocks do shareholders of Acrux own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN).

Company Calendar

• Last Earnings: 2/21/2019
• Today: 4/26/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: ASX:ACR
• CIK: N/A
• Web: www.acrux.com.au
• Phone: +61-3-83790100
• Fax: N/A
• Employees: 2,018
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,800,000.00
• Net Margins: -113.93%
• Pretax Margin: N/A
• Return on Equity: -130.13%
• Return on Assets: -48.18%

Debt

• Debt-to-Equity Ratio: 113.06
• Current Ratio: 1.61
• Quick Ratio: 2.89

Sales & Book Value

• Annual Sales: $5.09 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.57
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 290,720,000
• Free Float: N/A
• Market Cap: $12.47 million
• Optionable: Not Optionable
• Beta: 1.21